Envlo, a new diabetes drug developed by Daewoong Pharmaceutical, is entering long-term safety and efficacy testing of the Zemiglo three-drug therapy. While triple therapy of the Metformin+SGLT2i+DPP4i has been approved for reimbursement since last April, Daewoong Pharmaceutical is expected to establish its position as a latecomer, Envlo, in the triple therapy through this long-term trial. On the 13th, the Ministry of Food and Drug Safety approved the phase 3 clinical trial to evaluate the safety and efficacy of Envlo + Metformin + Gemigliptin applied by Daewoong Pharmaceutical. Envlo is the first domestically produced SGLT-2 type diabetes drug developed by Daewoong Pharmaceutical. It received approval in November 20